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Ambivalent Antihistamines
Warding off allergies with antihistamines
may prove to be dangerous for allergy suf-
ferers, if recent studies on mice are any
indication. The study found that three
widely used antihistamines stimulate tumor
growth in mice.
Lorne Brandes and colleagues at the
Manitoba Institute of Cell Biology at the
University of Manitoba in Winnipeg,
Canada, injected tumor culture lines into
mice and then administered antihistamines
daily in varying estimated human-equiva-
lent doses for 18-21 days. The researchers
then sacrificed the mice and surgically
removed the tumors. In comparing the
weights ofthe tumors, theyfound that three
of the five antihistamines tested caused the
tumors to grow heavier. This innovative
method differs from traditional tests for car-
cinogenicity, which involve administering a
substance to healthy laboratory animals; as a
result, the study-s conclu-
sions are being questioned.
The three antihista-
mines that were found to
cause the existing tumors
in the mice to grow larger
are loratadine, which is
used in Claritin, made by
Schering-Plough of Mad-
ison, New Jersey; astemi-
zole, the main ingredient
in Hismanal, made by
Janssen Pharmaceutica
Inc. of Titusville, New
Jersey; and hydroxyzine,
used in Atarax, made by
the Roerig Division of
Pfizer Inc. of New York.
Following the publication
of the study, the manu-
facturers of these drugs
issued statements defend-
ing their products and
criticizing the researchers'
human risk assessment
methods.
The two other drugs tested in the study
were cetrizine, which is used in Reactine,
also made by Pfizer, and doxylamine, used
in over-the-counter drugs such as NyQuil
and Unisom, which were not found to
stimulate tumor growth.
The researchers defend their methods in
the report of the study, saying, "Although
the potential for carcinogenicity has
received considerable attention in preclini-
cal drug testing in rodents, the propensity
of pharmaceuticals to enhance the growth
of existing tumors or the development of
malignancy induced by chemical or viral
initiators has been neglected."
The study was published in the 18 May
1994 issue of the Journal ofthe National
Cancer Institute along with an editorial
written by Douglas L. Weed, of the
Preventive Oncology Branch, Division of
Cancer Prevention and Control, of the
National Cancer Institute. Weed raised
questions about the human risk assessment
methods that were involved in the study
and called for further research, recom-
mending that no immediate changes be
made in the use ofthe antihistamines.
Brandes had called on the Food and
Drug Administration to change the labeling
on the antihistamines, but the FDA said
such a move would be premature. In a press
release, the agencysaid that standard carcino-
genicity tests with the antihistamines in mice
and rats do not demonstrate carcinogenicity
and the FDA believes that further study is
needed before any action is taken. The FDA
advised consumers that short term use ofthe
antihistamines is not at issue.
The agency is taking the study seriously,
however. Researchers at the FDA plan to
-~~~~~~~~ l -~~~~~~~~~~~~~~l
- l~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~cc
-~~~~~~
Canecr chaos. There are as many theories on how cancer is caused as there are scien-~~~~~(
tists studying it.~~~~~~~~~~~~~~~
duplicate the study and reevaluate the
human risk assessment methods. According
to Joseph DeGeorge, supervisory pharma-
cologist in the Division of Oncology and
Pulmonary Drug Products at the FDA,
researchers will not onlyduplicate the study,
but will extend their research to include
modifications to Brandes' work. For exam-
ple, DeGeorge said that human tumors may
different than the tumor types that Brandes
used. "We are trying to extend to other
tumor types and other assays." The FDA is
interacting very closely with Brandes in
duplicating hiswork, DeGeorge said.
The FDA will also examine another
innovative method used in Brandes' study
pertaining to how tumors respond to
increasing doses ofantihistamines. Brandes
found that the dose-response rate forms a
bell curve, with little response at low doses
and high doses, and heavy response at mid-
sized doses. In the past, researchers have
generally assumed that response increases
linearly as dose increases.
Brandes' finding implies that traditional
research involving only the administration
ofhigh doses could have missed high levels
ofresponse at mid-sized doses.
Meeting of the Cancer Minds
A recent meeting brought together scientists
conducting cancer research using informa-
tion gained from studies using species "rang-
ing from bacteria to yeast to fruit flies to
mice to humans," as described by Richard
Paules, coordinator of the conference on
Molecular Mechanisms of Environmental
Carcinogenesis. The meeting, held at the
NIEHS September 19-20, was a chance for
researchers from diverse areas to present the
most recent advancements in
environmental cancer reseach.
Perhaps the most exciting
and certainly the most publi-
cized information presented
at the conference was the iso-
lation of BRCA1, the gene
for inherited susceptibility to
breast cancer by a team of
researchers from several insti-
tutions including the NIEHS
and the University of Utah
School of Medicine. Several
other presentations high-
lighted recent advance in
cancer knowledge in such
areas as the varying conse-
quences ofgenetic damage in
animals with different genetic
backgrounds; the correlation
between the appearance of
Li-Fraumeni syndrome in
young children caused by
genetic mutations in the p53
gene and the appearance of
cancers from the same type of-mutations in
their parents and grandparents later in life;
identification of a mutation in an area of
chromosome 14q which may be developed
as a prognostic tool for endometrial cancer;
and an update on research of the effect of
exogenous estrogens on rates ofendometri-
al and breast cancers.
Researcher Amy Moser ofthe McArdle
Laboratory for Cancer Research at the
University of Wisconsin School of
Medicine presented studies supporting the
theory that particular genetic mutations, in
combination with particular environmen-
tal toxicants, may result in different conse-
quences; for example, mutations may pro-
duce a lot oftumors or no tumors depend-
ing on the genetic makeup of the individ-
ual in which they occur. Moser's studies
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involved mice with a Min (multiple intesti-
nal neoplasia) mutation in a gene that
appears to be involved in human colon
cancers. This mutation predisposes mice to
intestinal tumors, and mammary tumors in
the presence of ethylnitrosourea, an alky-
lating agent that damages DNA. Moser
and colleagues also identified a gene,
named MOM-1 (modifier of Min-1) that
reduces the number of tumors the mice
will get due to the Min-1 mutation.
Scientists from the M.D. Anderson
Cancer Center at the University ofTexas
Medical Center presented epidemiological
research on the inheritance of germline
p53 mutations which suggests that envi-
ronmental factors may affect the develop-
ment of tumors. Epidemiologist Louise
Strong and colleagues characterized the
incidence of Li-Fraumeni Syndrome-type
soft tissue sarcomas and osteosarcomas in
20 U.S. and Canadian families not previ-
ously identified as cancer carriers. 'When
looking at families ofchildren (aged 6-16)
who had Li-Fraumeni syndrome, Strong
found that the parents and grandparents of
these children also developed Li-Fraumeni-
type cancers later in life (in their 50s and
60s). This finding is significant because it
may show that environmental factors are
acting on the increased genetic instability
due to the p53 mutations passed through
the germline causing these cancers to occur
at younger and younger ages in consecutive
generations. According to Strong, this
approach to studying families may allow
researchers to determine can-
cer risk by sex, generation,
mutation type, and cancer
site in carriers of p53 germ-
line mutations.
Research presented byJeff
Boyd of the University of
Pennsylvania Medical Center
may be useful in determining
which women with endome-
trial cancer will have a poor
prognosis from the disease.
Boyd has identified a muta-
tion in chromosome 14q that
correlates with terminal type
II endometrial cancers. Scien-
tists may potentially use this
genetic marker as a prognos-
tic tool. This mutation may
also be involved in the devel-
opment of other estrogen-
related cancers as well.
Epidemiologist Barbara S.
Hulka of the University of
North Carolina School of
Public Health provided an
update on the relative risk to
women ofcancer from expo-
sure to exogenous estrogens
through use of oral contra-
ceptives and estrogen replacement therapy
(ERT). Hulka stated that use ofERT over
periods of 10-15 years may increase the
risk of endometrial cancer by as much as
10-fold; however, this risk may be reduced
or eliminated by adding progestin to the
therapy. Similarly, use of combined estro-
gen/progestin oral contraceptives for 3-5
years also reduces the risk of endometrial
cancer to half that of nonusers. However,
women who begin use of combination
product oral contraceptives as teenagers
may slightly increase their risk of breast
cancer.
Paules said ofthe meeting, "I think it is
really important for cancer researchers to
see the diversity of research. We get very
focused on our own little areas ... It's real-
ly important to step back and look at the
broader picture of cancer research to see
how to better design our experiments and
where we fit in." Over 250 scientists
attended the conference, which was co-
sponsored by Burroughs Wellcome, the
Chemical Industry Institute ofToxicology,
the Genotoxicity and Environmental
Mutagen Society, Glaxo, the North
Carolina Biotechnology Center, and
Procter & Gamble.
Taking the Lead on Lead
"In some cases soil cleanup benefits human
health, but in other cases, a community
may panic, spend millions of dollars on
cleanup, then find it hasn't helped," said
Bobby Wixson, chairman of the interna-
tional Society for Environmental
Geochemistry and Health task force on
lead in soil, in announcing a new approach
to lead cleanup.
SEGH's report, which calls for a flexi-
ble, case-by-case approach to risk assess-
ment for lead in soil, is the result of six
years ofstudy ofthe issue by the task force,
which included scientists, physicians, envi-
ronmental regulators, and industry repre-
sentatives. "This is the most comprehen-
sive scientific study to date on this issue,"
said Brian E. Davies, an internationally
recognized soil scientist and co-chairman
ofthe SEGH task force.
The task force proposes an approach
which moves away from the "dirt-eating
child" test for what levels of lead may
remain in soil, to a formula that takes into
account factors such as the future use of
the property (for example, as an industrial
site versus a playground); actual levels of
lead in the blood ofaffected people in the
area; bioavailability of lead-that is, its
ability to be absorbed by the body-which
varies with lead's composition and particle
size; and economic factors. Wixson said,
"This system will help communities decide
the best use of their money to protect the
most people."
According to the SEGH report, as of
1993, lead had been found at 922 of the
1,300 Superfund sites slated for priority
cleanup bythe EPA. However, factors such
as pollution from leaded gasoline, flaking
lead paint, and other sources oflead conta-
mination complicate cleanup issues.
The EPA estimates that 12 million
U.S. children under age 6 may be exposed
to soil with high levels of toxic lead.
Because health effects oflead exposure may
include reduced intelligence and growth in
children, miscarriage and premature birth
in pregnant women, and lowered birth
weight and decreased mental ability in
infants born to exposed mothers, the EPA
considers lead poisoning to be the most
serious environmental health threat to
young children.
Panelist Rufus Chaney of the USDA's
Agricultural Research Service estimates
more than 23% ofurban gardens may con-
tain more than 500 ppm oflead. Studies at
Central Michigan University indicate the
problem is not just urban, citing findings
ofmedian lead levels in soil near the foun-
dation of older homes of 960 ppm.
Currently, under EPA standards, soil with
more than 500 to 1,000 parts per million
of lead is considered hazardous and
cleanup is recommended. The SEGH
panel opposes setting a single ceiling for
lead in soil above which cleanup would be
recommended, preferring a case-by-case
approach.
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